Junichi Matsubara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Junichi Matsubara has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Kumi Mukai
Department of Clinical Oncology, Kyoto University Hospital, 54 Shogoinkawahara-Cho, Sakyo-Ku, Kyoto, 606-8507, Japan
2 shared publications- Manabu Muto
Kyoto University Graduate School of Medicine
2 shared publications - Akihisa Fukuda
Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
1 shared publication Asahi Sato
Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
1 shared publication- Dalong Qian
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA (USA)
1 shared publication - Debashis Sahoo
Department of Pediatrics, University of California San Diego, La Jolla, USA
1 shared publication
Latest Publications
- Open Access
- 18 July 2025
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 30 (9) , 1692-1699
The nationwide survey of Japanese public opinion about off-label use of anticancer drugs recommended by comprehensive genomic profiling
Background: Comprehensive genomic profiling (CGP)-guided precision medicine enables identification of molecular-based recommended therapy (MBRT), including off-label uses of anticancer drugs for rare genomic alterations. However, in Japan, access to such off-label drugs is limited despite their potential therapeutic benefits. This study aimed to investigate public attitudes toward off-label use of anticancer drugs in Japan. Methods: A nationwide online survey was conducted in Japan from February 15 to 19, 2024, targeting cancer patients (CA), medical professionals (MP), and non-cancer volunteers (non-CA) aged 40 + years. This included explanatory materials on CGP and MBRT, and questionnaires assessing willingness to use off-label drugs in various cost scenarios. Results: A total of 1,261 responses were analyzed: 419 CA, 430 MP, and 412 non-CA participants (median age: 59, range 40–89). Approximately 80% of MPs reported high comprehension of the explanatory materials (Top-2 box on a 5-point Likert scale), compared with ~ 60% of CA and < 50% of non-CA participants. Willingness to use off-label drugs (Top-2 box) was as follows: “No cost burden”: 51% CA, 62% MP, and 50% non-CA; “Cost ¥200,000 per month (approximately $US1,300)”: 15% CA, 31% MP, and 15% non-CA; “Cost ¥1,000,000 per month (approximately $US6,700)”: 6% CA, 16% MP, and 4% non-CA. Higher comprehension of explanatory materials was associated with greater willingness to use off-label drugs. Conclusions: Over half of respondents were willing to use off-label anticancer drugs if they were free of charge. However, willingness declined significantly with cost. Policy frameworks are needed in Japan to improve access to CGP-guided off-label therapies.
- 18 July 2025
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 30 (9) , 1692-1699
Open AccessThe nationwide survey of Japanese public opinion about off-label use of anticancer drugs recommended by comprehensive genomic profiling
Background: Comprehensive genomic profiling (CGP)-guided precision medicine enables identification of molecular-based recommended therapy (MBRT), including off-label uses of anticancer drugs for rare genomic alterations. However, in Japan, access to such off-label drugs is limited despite their potential therapeutic benefits. This study aimed to investigate public attitudes toward off-label use of anticancer drugs in Japan. Methods: A nationwide online survey was conducted in Japan from February 15 to 19, 2024, targeting cancer patients (CA), medical professionals (MP), and non-cancer volunteers (non-CA) aged 40 + years. This included explanatory materials on CGP and MBRT, and questionnaires assessing willingness to use off-label drugs in various cost scenarios. Results: A total of 1,261 responses were analyzed: 419 CA, 430 MP, and 412 non-CA participants (median age: 59, range 40–89). Approximately 80% of MPs reported high comprehension of the explanatory materials (Top-2 box on a 5-point Likert scale), compared with ~ 60% of CA and < 50% of non-CA participants. Willingness to use off-label drugs (Top-2 box) was as follows: “No cost burden”: 51% CA, 62% MP, and 50% non-CA; “Cost ¥200,000 per month (approximately $US1,300)”: 15% CA, 31% MP, and 15% non-CA; “Cost ¥1,000,000 per month (approximately $US6,700)”: 6% CA, 16% MP, and 4% non-CA. Higher comprehension of explanatory materials was associated with greater willingness to use off-label drugs. Conclusions: Over half of respondents were willing to use off-label anticancer drugs if they were free of charge. However, willingness declined significantly with cost. Policy frameworks are needed in Japan to improve access to CGP-guided off-label therapies.
- Open Access
- 21 April 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (6) , 889-897
Proposing oligo-recurrence criteria in pancreatic ductal adenocarcinoma: A stratified analysis of locoregional treatment benefits
- 21 April 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (6) , 889-897
Open AccessProposing oligo-recurrence criteria in pancreatic ductal adenocarcinoma: A stratified analysis of locoregional treatment benefits
- Open Access
- 11 April 2025
- Published by Wiley in Cancer Science
- Vol. 116 (7) , 1908-1919
First‐Line Genomic Profiling in Previously Untreated Advanced Solid Tumors: 1‐Year Follow‐Up of the FIRST‐Dx Study
The FIRST‐Dx study prospectively evaluated the clinical utility of the comprehensive genomic profiling (CGP) test (FoundationOne CDx) in the first‐line setting for patients with chemotherapy‐naïve advanced solid tumors (gastrointestinal, biliary, pancreatic, lung, breast, gynecologic, melanoma) in six hospitals in Japan. Here, we report the results of the 1‐year interim analysis of the follow‐up study about the clinical benefits provided by the upfront CGP test. The primary endpoint was overall survival (OS), and secondary endpoints were the proportion of patients who actually received molecular‐based recommended therapy (MBRT) determined by the molecular tumor board, best overall response rate (ORR) in each line of therapy, and progression‐free survival (PFS) ratio (PFS on MBRT/PFS on the first‐line therapy). Data from 172 patients with a median follow‐up of 15.1 months (range: 0.1–21.5 months) were available. The median OS was not reached. Thirty‐nine patients (22.7%) received MBRT during this follow‐up period. ORR in first‐line therapy was 56.3% in the MBRT group (n = 16) vs. 42.3% in the non‐MBRT group (n = 137), and in the second‐line was 26.3% in the MBRT group (n = 19) vs. 17.1% in the non‐MBRT group (n = 82). Regarding the PFS ratio of second‐line MBRT (n = 12), the median PFS ratio was 1.1, and four patients (33.3%) had a ratio ≥ 1.3, indicating that MBRT might be effective in changing the clinical outcome. The findings of this study imply that CGP testing before the standard of care for patients with advanced solid tumors could prove to be a clinically beneficial strategy for guiding subsequent precision anticancer treatments.Trial Registration: Japan Registry of Clinical Trials (jRCT) ID: jRCT1050220041
- 11 April 2025
- Published by Wiley in Cancer Science
- Vol. 116 (7) , 1908-1919
Open AccessFirst‐Line Genomic Profiling in Previously Untreated Advanced Solid Tumors: 1‐Year Follow‐Up of the FIRST‐Dx Study
The FIRST‐Dx study prospectively evaluated the clinical utility of the comprehensive genomic profiling (CGP) test (FoundationOne CDx) in the first‐line setting for patients with chemotherapy‐naïve advanced solid tumors (gastrointestinal, biliary, pancreatic, lung, breast, gynecologic, melanoma) in six hospitals in Japan. Here, we report the results of the 1‐year interim analysis of the follow‐up study about the clinical benefits provided by the upfront CGP test. The primary endpoint was overall survival (OS), and secondary endpoints were the proportion of patients who actually received molecular‐based recommended therapy (MBRT) determined by the molecular tumor board, best overall response rate (ORR) in each line of therapy, and progression‐free survival (PFS) ratio (PFS on MBRT/PFS on the first‐line therapy). Data from 172 patients with a median follow‐up of 15.1 months (range: 0.1–21.5 months) were available. The median OS was not reached. Thirty‐nine patients (22.7%) received MBRT during this follow‐up period. ORR in first‐line therapy was 56.3% in the MBRT group (n = 16) vs. 42.3% in the non‐MBRT group (n = 137), and in the second‐line was 26.3% in the MBRT group (n = 19) vs. 17.1% in the non‐MBRT group (n = 82). Regarding the PFS ratio of second‐line MBRT (n = 12), the median PFS ratio was 1.1, and four patients (33.3%) had a ratio ≥ 1.3, indicating that MBRT might be effective in changing the clinical outcome. The findings of this study imply that CGP testing before the standard of care for patients with advanced solid tumors could prove to be a clinically beneficial strategy for guiding subsequent precision anticancer treatments.Trial Registration: Japan Registry of Clinical Trials (jRCT) ID: jRCT1050220041
- Open Access
The E2F4 transcriptional repressor is a key mechanistic regulator of colon cancer resistance to irinotecan (CPT-11)
Background. Colorectal carcinomas (CRCs) are seldom eradicated by cytotoxic chemotherapy. Cancer cells with stem-like functional properties, often referred to as “cancer stem cells” (CSCs), display preferential resistance to several anti-tumor agents used in cancer chemotherapy, but the molecular mechanisms underpinning their selective survival remain only partially understood. Methods. In this study, we used Transcription Factor Target Genes (TFTG) enrichment analysis to identify transcriptional regulators (activators or repressors) that undergo preferential activation by chemotherapy in CRC cells with a “bottom-of-the-crypt” phenotype (EPCAM + /CD44 + /CD166 + ; CSC-enriched) as compared to CRC cells with a “top-of-the-crypt” phenotype (EPCAM + /CD44 neg /CD166 neg ; CSC-depleted). The two cell populations were purified in parallel by fluorescence-activated cell sorting (FACS) from a patient-derived xenograft (PDX) line representative of a moderately differentiated human CRC, following in vivo chemotherapy with irinotecan (CPT-11). The transcriptional regulators identified as differentially activated were tested for differential expression in normal vs. cancer tissues, and in cell populations enriched in stem/progenitor cell-types as compared to differentiated lineages (goblet cells, enterocytes) in the mouse colon epithelium. Finally, the top candidate was tested for mechanistic contribution to drug-resistance by selective down-regulation using short-hairpin RNAs (shRNAs). Results. Our analysis identified E2F4 and TFDP1, two core components of the DREAM transcriptional repression complex, as transcriptional modulators preferentially activated by irinotecan in EPCAM + /CD44 + /CD166 + as compared to EPCAM + /CD44 neg /CD166 neg cancer cells. The expression levels of both genes ( E2F4 , TFDP1 ) were found up-regulated in CRCs as compared to human normal colon tissues, and in a sub-population of mouse colon epithelial cells enriched in stem/progenitor elements (Epcam + /Cd44 + /Cd66a low /Kit neg ) as compared to other sub-populations enriched in either goblet cells (Epcam + /Cd44 + /Cd66a low /Kit + ) or enterocytes (Epcam + /Cd44 neg /Cd66a high ). Most importantly, E2F4 down-regulation using shRNAs dramatically enhanced the sensitivity of human CRCs to in vivo treatment with irinotecan , across three independent PDX models. Conclusions. Our data identified E2F4 and the DREAM repressor complex as critical regulators of human CRC resistance to irinotecan , and as candidate targets for the development of chemo-sensitizing agents.
Open AccessThe E2F4 transcriptional repressor is a key mechanistic regulator of colon cancer resistance to irinotecan (CPT-11)
Background. Colorectal carcinomas (CRCs) are seldom eradicated by cytotoxic chemotherapy. Cancer cells with stem-like functional properties, often referred to as “cancer stem cells” (CSCs), display preferential resistance to several anti-tumor agents used in cancer chemotherapy, but the molecular mechanisms underpinning their selective survival remain only partially understood. Methods. In this study, we used Transcription Factor Target Genes (TFTG) enrichment analysis to identify transcriptional regulators (activators or repressors) that undergo preferential activation by chemotherapy in CRC cells with a “bottom-of-the-crypt” phenotype (EPCAM + /CD44 + /CD166 + ; CSC-enriched) as compared to CRC cells with a “top-of-the-crypt” phenotype (EPCAM + /CD44 neg /CD166 neg ; CSC-depleted). The two cell populations were purified in parallel by fluorescence-activated cell sorting (FACS) from a patient-derived xenograft (PDX) line representative of a moderately differentiated human CRC, following in vivo chemotherapy with irinotecan (CPT-11). The transcriptional regulators identified as differentially activated were tested for differential expression in normal vs. cancer tissues, and in cell populations enriched in stem/progenitor cell-types as compared to differentiated lineages (goblet cells, enterocytes) in the mouse colon epithelium. Finally, the top candidate was tested for mechanistic contribution to drug-resistance by selective down-regulation using short-hairpin RNAs (shRNAs). Results. Our analysis identified E2F4 and TFDP1, two core components of the DREAM transcriptional repression complex, as transcriptional modulators preferentially activated by irinotecan in EPCAM + /CD44 + /CD166 + as compared to EPCAM + /CD44 neg /CD166 neg cancer cells. The expression levels of both genes ( E2F4 , TFDP1 ) were found up-regulated in CRCs as compared to human normal colon tissues, and in a sub-population of mouse colon epithelial cells enriched in stem/progenitor elements (Epcam + /Cd44 + /Cd66a low /Kit neg ) as compared to other sub-populations enriched in either goblet cells (Epcam + /Cd44 + /Cd66a low /Kit + ) or enterocytes (Epcam + /Cd44 neg /Cd66a high ). Most importantly, E2F4 down-regulation using shRNAs dramatically enhanced the sensitivity of human CRCs to in vivo treatment with irinotecan , across three independent PDX models. Conclusions. Our data identified E2F4 and the DREAM repressor complex as critical regulators of human CRC resistance to irinotecan , and as candidate targets for the development of chemo-sensitizing agents.